Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 06.09.2022
Formycon AG
Press Release // September 6, 2022
Formycon publishes preliminary figures for the first half of 2022
Reporting at Group level for the first time under IFRS (International Financial Reporting Standards)
Preliminary figures overall in line with forecast: Preliminary Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20.3 million) and prel [ … ]
Tue, 06.09.2022
Formycon AG
Press Release // September 6, 2022
Formycon publishes preliminary figures for the first half of 2022
Reporting at Group level for the first time under IFRS (International Financial Reporting Standards)
Preliminary figures overall in line with forecast: Preliminary Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20.3 million) and prel [ … ]
Tue, 30.08.2022
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 97,00 auf EUR 103,00.
Zusammenfassung:
Am 26. August gab Formycon die Zulassung ihres Lucentis-Biosimilars,
FYB201, durch die Europäische [ … ]
Tue, 30.08.2022
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 97,00 auf EUR 103,00.
Zusammenfassung:
Am 26. August gab Formycon die Zulassung ihres Lucentis-Biosimilars,
FYB201, durch die Europäische [ … ]
Mon, 29.08.2022
Formycon AG
Press Release, August 29, 2022
European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2
Munich, Amsterdam, Zug – Formycon AG (“Formycon”), Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorizat [ … ]
Mon, 29.08.2022
Formycon AG
Press Release, August 29, 2022
European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2
Munich, Amsterdam, Zug – Formycon AG (“Formycon”), Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorizat [ … ]
Fri, 26.08.2022
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 26, 2022
Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the European Commission (“EC”) today has granted marketi [ … ]
Fri, 26.08.2022
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 26, 2022
Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the European Commission (“EC”) today has granted marketi [ … ]
Tue, 16.08.2022
Formycon AG
Press Release // August 16, 2022
Formycon’s Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study
VESPUCCI study demonstrates the comparable efficacy of FYB202 to the reference product Stelara® in patients with moderate to severe psoriasis vulgaris (plaque psoriasis)
Primary Effic [ … ]
Tue, 16.08.2022
Formycon AG
Press Release // August 16, 2022
Formycon’s Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study
VESPUCCI study demonstrates the comparable efficacy of FYB202 to the reference product Stelara® in patients with moderate to severe psoriasis vulgaris (plaque psoriasis)
Primary Effic [ … ]